Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome

  • Benjamin Chu Division of Hematology, Department of Internal Medicine, Ohio State University
  • Arwa Shana'ah Department of Pathology, Ohio State University
  • Craig C Hofmeister Division of Hematology, Department of Internal Medicine, Ohio State University
  • Don M Benson Division of Hematology, Department of Internal Medicine, Ohio State University
  • Yvonne A Efebera Division of Hematology, Department of Internal Medicine, Ohio State University

Keywords

lenalidomide, POEMS

Abstract

Lenalidomide is an effective therapy against malignant plasma cells and a potent agent against proinflammatory and proangiogenic cytokines. The use of lenalidomide in POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein with plasma cells, skin changes) has been reported, but its benefit in long-term use is not well established. A 55-year-old man with POEMS and debilitating polyneuropathy was treated with lenalidomide and dexamethasone followed by maintenance lenalidomide. He remains in haematologic remission and in complete recovery of functional status 3.5 years after diagnosis. This case supports the long-term use of lenalidomide in patients with POEMS syndrome.

VIEW THE ENTIRE ARTICLE

References

Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature, Medicine 1980;59:311–322.

Dispenzieri A. POEMS syndrome: update on diagnosis, risk-stratification, and management, Am J Hematol 2012;87:804–814.

Dispenzieri A. How I treat POEMS syndrome, Blood 2012;119:5650–5658.

Li J, Zhou DB. New advances in the diagnosis and treatment of POEMS syndrome, Br J Haematol 2013;161:303–315.

D’Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience, Blood 2012;120:56–62.

Tomas JF, Giraldo P, Lecumberri R, Nistal S. POEMS syndrome with severe neurological damage clinically recovered with lenalidomide, Haematologica 2012;97:320–322.

Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome, Blood 2007;110:1075–1076.

Tang X, Shi X, Sun A, Qiu H, Gu B, Zhou H, et al. Successful bortezomib-based treatment in POEMS syndrome, Eur J Haematol 2009;83:609–610.

McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma, N Engl J Med 2012;366:1770–1781.

Published: 2014-10-22

Issue: Vol. 1 (2014) (view)

Section: Articles

How to cite:
1.
Chu B, Shana’ah A, Hofmeister CC, Benson DM, Efebera YA. Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome. EJCRIM [Internet]. 2014Oct.22 [cited 2020Sep.26];1(1). Available from: https://ejcrim.com/index.php/EJCRIM/article/view/93